CYP11B2

Summary

CYP11B2 (cytochrome P450 family 11 subfamily B member 2, HGNC:2592) is a protein-coding gene on chromosome 8q24.3, encoding Cytochrome P450 11B2, mitochondrial (P19099). A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the mitochondrial inner membrane. The enzyme has steroid 18-hydroxylase activity to synthesize aldosterone and 18-oxocortisol as well as steroid 11 beta-hydroxylase activity. Mutations in this gene cause corticosterone methyl oxidase deficiency.

Source: NCBI Gene 1585 — RefSeq curated summary.

At a glance

• Gene–disease (curated): familial hyperreninemic hypoaldosteronism type 2 (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 16
• Clinical variants (ClinVar): 658 total — 49 pathogenic, 43 likely-pathogenic
• Phenotypes (HPO): 39
• Druggable target: yes — 12 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000498

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2592
Approved symbol	CYP11B2
Name	cytochrome P450 family 11 subfamily B member 2
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	CYP11BL, CPN2, P-450C18, P450aldo, ALDOS
Ensembl gene	ENSG00000179142
Ensembl biotype	protein_coding
OMIM	124080
Entrez	1585

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000323110, ENST00000945895, ENST00000945896

RefSeq mRNA: 1 — MANE Select: NM_000498 NM_000498

CCDS: CCDS6393

Canonical transcript exons

ENST00000323110 — 9 exons

Exon	Start	End
ENSE00001225434	142912530	142912727
ENSE00001301821	142917602	142917843
ENSE00001387551	142910559	142912093
ENSE00001638180	142914705	142914908
ENSE00001649336	142915046	142915245
ENSE00001690999	142912807	142912885
ENSE00001738697	142917059	142917214
ENSE00001785304	142913285	142913451
ENSE00001786255	142914264	142914418

Expression profiles

Bgee: expression breadth broad, 30 present calls, max score 92.72.

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	92.72	gold quality
right adrenal gland	UBERON:0001233	92.16	gold quality
left adrenal gland	UBERON:0001234	90.22	gold quality
adrenal cortex	UBERON:0001235	88.61	gold quality
adrenal gland	UBERON:0002369	87.86	gold quality
left adrenal gland cortex	UBERON:0035825	86.98	gold quality
gluteal muscle	UBERON:0002000	84.79	gold quality
parotid gland	UBERON:0001831	84.72	gold quality
heart right ventricle	UBERON:0002080	83.39	gold quality
triceps brachii	UBERON:0001509	82.10	gold quality
inferior olivary complex	UBERON:0002127	79.43	gold quality
tongue squamous epithelium	UBERON:0006919	78.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.28	silver quality
choroid plexus epithelium	UBERON:0003911	76.98	gold quality
olfactory bulb	UBERON:0002264	76.83	gold quality
vena cava	UBERON:0004087	76.78	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	76.63	gold quality
cervix squamous epithelium	UBERON:0006922	76.35	gold quality
type B pancreatic cell	CL:0000169	75.60	gold quality
nasal cavity epithelium	UBERON:0005384	75.54	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	74.55	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	74.49	gold quality
lateral nuclear group of thalamus	UBERON:0002736	73.58	gold quality
cerebellar vermis	UBERON:0004720	73.25	gold quality
body of tongue	UBERON:0011876	73.10	gold quality
biceps brachii	UBERON:0001507	72.77	gold quality
Brodmann (1909) area 46	UBERON:0006483	71.94	gold quality
endothelial cell	CL:0000115	71.88	gold quality
subthalamic nucleus	UBERON:0001906	71.75	gold quality
medulla oblongata	UBERON:0001896	71.50	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.98

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): APEX1, AR, ATF1, ATF2, C1QTNF1, CREB1, DMRT1, FOXL2, JUNB, NR2F1, NR4A1, NR4A2, NR5A1, REST, TCF3

miRNA regulators (miRDB)

41 targeting CYP11B2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-549A-3P	99.54	68.17	825
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-6080	99.43	69.43	373
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-6878-3P	99.24	64.23	920
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-18B-3P	98.05	65.55	595
HSA-MIR-6072	98.00	66.47	804
HSA-MIR-6765-3P	97.83	64.59	1165
HSA-MIR-3921	97.81	67.45	1431

Literature-anchored findings (GeneRIF, showing 40)

• The unmodified mitochondrial localization signal of human CYP11B2 is functional when expressed in fission yeast, and overexpression of the gene significantly enhances steroid hydroxylase activity of CYP11B2-expressing fission yeast cells. (PMID:11841224)
• Substrate recognition and conversion are attributed to the N-terminal part of human CYP11B2. (PMID:11856349)
• role in familial hyperaldosteronism (PMID:11903322)
• Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1 (PMID:11932209)
• investigate the relationship of gene polymorphism of angiotension converting enzyme (ACE), aldosterone synthase (CYP11B2) with essential hypertension (EH) and left ventricular hypertrophy (LVH) in hypertensive patients (PMID:12133420)
• Expression of aldosterone synthase gene in failing human heart (PMID:12161536)
• Carotid and femoral intima-media thickness were assessed in subjects genotyped for the presence of the ACE D, aldosterone synthase -344T and alpha-adducin 460Trp alleles. (PMID:12172317)
• CaMKI is involved in angiotensin II and K(+) stimulation of CYP11B2 transcription and the capacity of the adrenal to produce aldosterone (PMID:12193581)
• Inter-individual variation of blood pressure and plasma aldosterone is affected by the interaction of C(-344)T polymorphism and ageing. (PMID:12195120)
• Variation in locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio (PMID:12213905)
• CT genotype of CYP11B2 gene may be one of factors responsible for the pathogenesis of hypertrophic cardiomyopathy HCM in a proportion of patients. (PMID:12376254)
• The study of association of CYP11B2 polymorphism with hypertension in Russian patients in Bashkorstan (PMID:12391843)
• Contrasting associations between these variants and essential hypertension do not necessarily exclude the possibility that other, as yet undefined, variants of the aldosterone synthase gene could be linked with hypertension in black people. (PMID:12544440)
• Genetic variation in or near the CYP11B2 gene is a possible genetic marker for the progression of renal dysfunction in females with IgA nephropathy, but not in males (PMID:12746403)
• Linear modeling of postural changes in renin and aldosterone showed a maximal achievable aldosterone increase of 110 pmol/liter with no mutated haplotype and 500 pmol/liter with two mutated haplotypes. Molecular basis for aldosterone production. (PMID:12788845)
• Exon 3 mutation (C554T, leading to amino acid T185I) and exon 9 mutation (A1492G, leading to T498A)localize to beta 3-sheet in cytochrome P450 enzyme structure. Aldosterone synthase catalyzes oxygenation of the C(18) carbon of steroid substrates. (PMID:12788848)
• The T-344C and A6547G, but not the T4986C, variants of the aldosterone synthase gene are associated with HT in females of the Anglo-Celtic population studied. (PMID:12817181)
• A variant within the CYP11B2 locus has a clinically important impact on the severity of SBP changes in individuals with newly diagnosed hypertension who are of African ethnicity. (PMID:14643573)
• Our data suggest that -344C/T polymorphism in the promoter region of the aldosterone synthase gene affects left ventricular mass and thickness in essential hypertension, independent of adrenal aldosterone. (PMID:14736447)
• -344C/T polymorphism in CYP11B2 was considered an independent genetic factor possibly associated with hypertension or atherosclerotic diseases in the Japanese population. (PMID:15055249)
• identified two new variants in CYP11B2, a C/T single nucleotide exchange located in the first intron and a double nucleotide exchange at the 3’-splice site of exon 8 (PMID:15062555)
• The ACE I/D, alpha-adducin Gly460Trp and aldosterone synthase -344C/T polymorphisms interact to influence systolic blood pressure in Chinese, suggesting that these genes might indeed predispose to hypertension (PMID:15097233)
• Aldosterone synthase genotype is unrelated to overall coronary artery disease events risk in male patients. (PMID:15135254)
• TT genotype of T-344C polymorphism of aldosterone synthase gene was associated with significantly higher levels of plasma renin in normotensive men (PMID:15223724)
• CYP11B2 C-344T and AT1R A1166C polymorphisms affect the autonomic modulation of heart rate, but these genetic effects depend on sodium excretion. (PMID:15238568)
• In multi-ethnic population, C-344T CYP1B2 polymorphism is associated with blood pressure, plasma aldosterone levels and aldosterone-to-renin ratio. Significant differences in allele frequencies between groups. Ethnicity does not explain results. (PMID:15361760)
• Renal function in relation to ALDOS was studied in a Han population. (PMID:15378162)
• The results suggest that -344T/C polymorphism of CYP11B2 gene may be associated with low-renin essential hypertension in the Han nationality in Shandong province. (PMID:15505931)
• Molecular variant in CYP11B2 is in linkage disequilibrium (LD) with a key quantitative trait in CYP11B1. (PMID:15507509)
• Linkage disequilibrium between causative CYP11B1 variants and CYP11B2 polymorphisms account for urinary 11-deoxycortisol excretion. (PMID:15522937)
• may be polymorphic among mult=ethnic groups as a risk factor for hypertension (PMID:15545843)
• Aldo deficiency due to a compromised methyl oxidase step of Aldo synthesis favors extracellular volume depletion, and may account for an increased risk of placental hypoperfusion and consecutive development of preeclampsia (PMID:15569322)
• data support a physiological role of Ubc9 and PIAS1 as transcriptional coactivators in COUP-TFI-mediated CYP11B2 transcription (PMID:15611122)
• The CYP11B2 C-344T polymorphism affects arterial stiffness. However, sodium intake seems to modulate this genetic effect. (PMID:15614025)
• The correlation of the intron-2 conversion allele with high systolic blood pressure and plasma renin ratio associates it with hypertension. (PMID:15643128)
• Inactivating mutations cause aldosterone synthase deficiency. (PMID:15699546)
• The -344CC or intron 2 conversion (-/-) genotype in CYP11B2 may be a risk factor for developing sodium-sensitive cardiac hypertrophy. (PMID:15894890)
• aldosterone synthase gene polymorphism (ASGP) CYP11B2 influences the age-related changes in blood pressure (BP) and arterial stiffness in hypertensive subjects (PMID:15894891)
• Subjects with the combination of ACE DD and CYP11B2 CC genotypes might have a better blood pressure response to hydrochlorothiazide than the other genotypic combinations of these 2 genes. (PMID:16080804)
• The CYP11B-344C/T polymorphism is associated with small artery compliance, and TT genotype subjects are susceptible to abnormality of small arterial compliance. (PMID:16080805)

Cross-species orthologs

0 orthologs

Paralogs (2): CYP11A1 (ENSG00000140459), CYP11B1 (ENSG00000160882)

Protein

Protein identifiers

Cytochrome P450 11B2, mitochondrial — P19099 (reviewed: P19099)

Alternative names: Aldosterone synthase, Aldosterone-synthesizing enzyme, CYPXIB2, Corticosterone 18-monooxygenase, CYP11B2, Cytochrome P-450Aldo, Cytochrome P-450C18, Steroid 11-beta-hydroxylase, CYP11B2, Steroid 18-hydroxylase

All UniProt accessions (1): P19099

UniProt curated annotations — full annotation on UniProt →

Function. A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure. Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two successive oxidations at C18 yielding 18-hydroxy and then 18-oxo intermediates (that would not leave the enzyme active site during the consecutive hydroxylation reactions), ending with the formation of aldosterone. Can also produce 18-hydroxycortisol and 18-oxocortisol, derived from successive oxidations of cortisol at C18, normally found at very low levels, but significantly increased in primary aldosteronism, the most common form of secondary hypertension. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). Could also be involved in the androgen metabolic pathway.

Subcellular location. Mitochondrion inner membrane.

Tissue specificity. Expressed sporadically in the zona glomerulosa (zG) of the adrenal cortex (conventional zonation), as well as in aldosterone-producing cell clusters (APCCs) composed of morphological zG cells in contact with the capsule (variegated zonation).

Disease relevance. Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency) [MIM:203400] Autosomal recessive disorder of aldosterone biosynthesis. There are two biochemically different forms of selective aldosterone deficiency be termed corticosterone methyloxidase (CMO) deficiency type 1 and type 2. In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18-hydroxycorticosterone, is low or normal. The disease is caused by variants affecting the gene represented in this entry. Corticosterone methyloxidase 2 deficiency (CMO-2 deficiency) [MIM:610600] Autosomal recessive disorder of aldosterone biosynthesis. In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18-hydroxycorticosterone. Consequently, patients have a greatly increased ratio of 18-hydroxycorticosterone to aldosterone and a low ratio of corticosterone to 18-hydroxycorticosterone in serum. The disease is caused by variants affecting the gene represented in this entry.

Induction. Expression is induced by angiotensin II, potassium (K+), and also by cAMP.

Pathway. Steroid biosynthesis.

Miscellaneous. Expressed in aldosterone-secreting tumors and in adrenal glands of patients with idiopathic hyperaldosteronism.

Similarity. Belongs to the cytochrome P450 family.

RefSeq proteins (1): NP_000489* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001128	Cyt_P450	Family
IPR002399	Cyt_P450_mitochondrial	Family
IPR017972	Cyt_P450_CS	Conserved_site
IPR036396	Cyt_P450_sf	Homologous_superfamily
IPR050479	CYP11_CYP27_families	Family

Pfam: PF00067

Enzyme classification (BRENDA):

• EC 1.14.15.4 — steroid 11beta-monooxygenase (BRENDA: 16 organisms, 122 substrates, 309 inhibitors, 38 Km, 19 kcat entries)
• EC 1.14.15.5 — corticosterone 18-monooxygenase (BRENDA: 5 organisms, 15 substrates, 98 inhibitors, 3 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
11-DEOXYCORTICOSTERONE	0.0008–0.18	15
11-DEOXYCORTISOL	0.0084–0.338	6
CORTICOSTERONE	0.0059–0.087	4
ADRENAL FERREDOXIN	0.002–0.0024	2
DEOXYCORTICOSTERONE	0.006–0.02	2
4-ANDROSTENE-3,17-DIONE	0.013	1
CORTICOSTERONE	0.028	1

Catalyzed reactions (Rhea), 8 shown:

• corticosterone + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 18-hydroxycorticosterone + 2 oxidized [adrenodoxin] + H2O (RHEA:11872)
• a steroid + 2 reduced [adrenodoxin] + O2 + 2 H(+) = an 11beta-hydroxysteroid + 2 oxidized [adrenodoxin] + H2O (RHEA:15629)
• 11-deoxycortisol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = cortisol + 2 oxidized [adrenodoxin] + H2O (RHEA:46100)
• 21-hydroxyprogesterone + 2 reduced [adrenodoxin] + O2 + 2 H(+) = corticosterone + 2 oxidized [adrenodoxin] + H2O (RHEA:46104)
• 18-hydroxycorticosterone + 2 reduced [adrenodoxin] + O2 + 2 H(+) = aldosterone + 2 oxidized [adrenodoxin] + 2 H2O (RHEA:50792)
• cortisol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 18-hydroxycortisol + 2 oxidized [adrenodoxin] + H2O (RHEA:76019)
• 18-hydroxycortisol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 18-oxocortisol + 2 oxidized [adrenodoxin] + 2 H2O (RHEA:76023)
• 21-hydroxyprogesterone + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 18-hydroxy-11-deoxycorticosterone + 2 oxidized [adrenodoxin] + H2O (RHEA:76151)

UniProt features (70 total): helix 24, sequence variant 18, strand 13, sequence conflict 7, mutagenesis site 3, binding site 2, transit peptide 1, chain 1, turn 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
4DVQ	X-RAY DIFFRACTION	2.49
4FDH	X-RAY DIFFRACTION	2.71
6XZ9	X-RAY DIFFRACTION	2.77
7M8I	X-RAY DIFFRACTION	2.94
6XZ8	X-RAY DIFFRACTION	3
7M8V	X-RAY DIFFRACTION	3.08
4ZGX	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P19099-F1	90.10	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 381; 450 (axial binding residue)

Mutagenesis-validated functional residues (3):

Position	Phenotype
112	increases 11-beta- and 18-hydroxylase activities toward 11-deoxycorticosterone; increases 11-beta-hydroxylase activity t
147	increases 11-beta-hydroxylase activity toward 11-deoxycorticosterone and 11-deoxycortisol.
152	no significant effect on hydroxylase activities toward 11-deoxycorticosterone and 11-deoxycortisol.

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-193993	Mineralocorticoid biosynthesis
R-HSA-194002	Glucocorticoid biosynthesis
R-HSA-211976	Endogenous sterols
R-HSA-5579009	Defective CYP11B2 causes CMO-1 deficiency
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-196071	Metabolism of steroid hormones
R-HSA-211859	Biological oxidations
R-HSA-211897	Cytochrome P450 - arranged by substrate type
R-HSA-211945	Phase I - Functionalization of compounds
R-HSA-556833	Metabolism of lipids
R-HSA-5579029	Metabolic disorders of biological oxidation enzymes
R-HSA-5668914	Diseases of metabolism
R-HSA-8957322	Metabolism of steroids

MSigDB gene sets: 309 (showing top): MODULE_93, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_BIOLOGICAL_OXIDATIONS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GNF2_GSTM1, PEREZ_TP63_TARGETS, GOBP_GLUCOCORTICOID_METABOLIC_PROCESS, GOBP_RENAL_SYSTEM_PROCESS_INVOLVED_IN_REGULATION_OF_BLOOD_VOLUME, GNF2_HPN, GOBP_C21_STEROID_HORMONE_METABOLIC_PROCESS, GOBP_REGULATION_OF_SYSTEMIC_ARTERIAL_BLOOD_PRESSURE, GOBP_REGULATION_OF_HORMONE_LEVELS

GO Biological Process (19): regulation of blood volume by renal aldosterone (GO:0002017), renal water homeostasis (GO:0003091), C21-steroid hormone biosynthetic process (GO:0006700), glucocorticoid biosynthetic process (GO:0006704), mineralocorticoid biosynthetic process (GO:0006705), cholesterol metabolic process (GO:0008203), sterol metabolic process (GO:0016125), aldosterone biosynthetic process (GO:0032342), cellular response to hormone stimulus (GO:0032870), cortisol metabolic process (GO:0034650), cortisol biosynthetic process (GO:0034651), cellular response to potassium ion (GO:0035865), potassium ion homeostasis (GO:0055075), sodium ion homeostasis (GO:0055078), cellular response to peptide hormone stimulus (GO:0071375), alcohol metabolic process (GO:0006066), lipid metabolic process (GO:0006629), steroid biosynthetic process (GO:0006694), steroid metabolic process (GO:0008202)

GO Molecular Function (9): steroid 11-beta-monooxygenase activity (GO:0004507), iron ion binding (GO:0005506), steroid hydroxylase activity (GO:0008395), heme binding (GO:0020037), corticosterone 18-monooxygenase activity (GO:0047783), monooxygenase activity (GO:0004497), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), metal ion binding (GO:0046872)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Metabolism of steroid hormones	2
Metabolism	2
Cytochrome P450 - arranged by substrate type	1
Metabolic disorders of biological oxidation enzymes	1
Metabolism of steroids	1
Phase I - Functionalization of compounds	1
Biological oxidations	1
Diseases of metabolism	1
Disease	1
Metabolism of lipids	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
steroid hormone biosynthetic process	3
hormone biosynthetic process	2
glucocorticoid metabolic process	2
steroid metabolic process	2
primary alcohol biosynthetic process	2
ketone biosynthetic process	2
olefinic compound biosynthetic process	2
monoatomic cation homeostasis	2
inorganic ion homeostasis	2
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen	2
oxidoreductase activity	2
regulation of systemic arterial blood pressure by hormone	1
positive regulation of systemic arterial blood pressure	1
renal system process	1
multicellular organismal-level water homeostasis	1
C21-steroid hormone metabolic process	1
mineralocorticoid metabolic process	1
sterol metabolic process	1
secondary alcohol metabolic process	1
C21-steroid hormone biosynthetic process	1
mineralocorticoid biosynthetic process	1
aldosterone metabolic process	1
aldehyde biosynthetic process	1
response to hormone	1
cellular response to chemical stimulus	1
cellular response to endogenous stimulus	1
primary alcohol metabolic process	1
ketone metabolic process	1
olefinic compound metabolic process	1
tertiary alcohol metabolic process	1
glucocorticoid biosynthetic process	1
cortisol metabolic process	1
tertiary alcohol biosynthetic process	1
response to potassium ion	1
cellular response to metal ion	1
cellular response to hormone stimulus	1
response to peptide hormone	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
small molecule metabolic process	1

Protein interactions and networks

STRING

1708 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYP11B2	STAR	P49675	922
CYP11B2	REN	P00797	912
CYP11B2	HSD11B2	P80365	901
CYP11B2	AGT	P01019	897
CYP11B2	AGTR1	P30556	871
CYP11B2	ACE	P12821	864
CYP11B2	MC2R	Q01718	842
CYP11B2	NR5A1	Q13285	829
CYP11B2	POMC	P01189	818
CYP11B2	FDX1	P10109	812
CYP11B2	KCNJ5	P48544	812
CYP11B2	HSD3B2	P26439	794
CYP11B2	NR3C2	P08235	792
CYP11B2	ATP2B3	Q16720	763
CYP11B2	NR0B1	P51843	757

IntAct

0 interactions, top by confidence:

BioGRID (10): CYP11B2 (Negative Genetic), HMGA1 (Negative Genetic), SSTR5 (Negative Genetic), MAP3K10 (Negative Genetic), PIM1 (Negative Genetic), CYP11B2 (Negative Genetic), CYP11B2 (Affinity Capture-MS), CYP11B2 (Affinity Capture-Western), TRIM2 (Affinity Capture-Western), CYP11B2 (Co-crystal Structure)

ESM2 similar proteins: O15528, O35074, O46515, O77809, O77810, P00187, P00189, P05108, P05177, P10611, P10612, P14137, P14579, P14580, P14581, P15150, P15393, P15538, P15539, P17177, P17178, P19099, P30099, P30100, P51663, P79153, P79202, P97720, Q02318, Q02928, Q07217, Q16647, Q28827, Q29527, Q29552, Q29626, Q2XV99, Q4H4C3, Q5KQT6, Q5TCH4

Diamond homologs: A0A068Q5V6, A0A068Q605, A0A068Q7V0, A0A0C5QRZ2, A0A0D9MRV9, A0A0N7F297, A0A1B4XBH0, A0A1B4XBH8, A0A1D6F9Y9, A0A1D6HSP4, A0A1W5T1Y6, A0A2H5AIX6, A0A2K9RG08, A0A3Q9R4N5, A0A4D6Q414, A0A4D6Q415, A0A517FNC5, A0A8K1AW54, A2QBE8, A6YIH8, B1GVX3, B8NHD9, B8NHY4, C9K202, D1MX85, E9KMQ3, E9Q816, F2K081, F4JW83, G3XSI3, G4N2X2, G5EJN7, H2DH18, H2DH24, L0N063, L7HT17, M1KVN4, M1KXD0, O13345, O22203

SIGNOR signaling

9 interactions.

A	Effect	B	Mechanism
APEX1	“down-regulates quantity by repression”	CYP11B2	“transcriptional regulation”
NR5A1	“down-regulates quantity by repression”	CYP11B2	“transcriptional regulation”
CYP11B2	“up-regulates quantity”	cortisol	“chemical modification”
CYP11B2	“down-regulates quantity”	11-deoxycortisol	“chemical modification”
CYP11B2	“up-regulates quantity”	corticosterone	“chemical modification”
CYP11B2	“down-regulates quantity”	11-deoxycorticosterone	“chemical modification”
CYP11B2	“up-regulates quantity”	18-hydroxycorticosterone	“chemical modification”
CYP11B2	“up-regulates quantity”	aldosterone	“chemical modification”
metyrapone	“down-regulates activity”	CYP11B2	“chemical inhibition”

Disease & clinical

Clinical variants and AI predictions

ClinVar

658 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	49
Likely pathogenic	43
Uncertain significance	162
Likely benign	334
Benign	24

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1071836	NM_000498.3(CYP11B2):c.342_343dup (p.Pro115fs)	Pathogenic
1073733	NM_000498.3(CYP11B2):c.1276C>T (p.Gln426Ter)	Pathogenic
1074429	NC_000008.10:g.(?143998465)(143999600_?)del	Pathogenic
1374879	NM_000498.3(CYP11B2):c.553del (p.Thr185fs)	Pathogenic
1387027	NM_000498.3(CYP11B2):c.595+1del	Pathogenic
1414779	NM_000498.3(CYP11B2):c.1034_1047del (p.Leu345fs)	Pathogenic
1416764	NM_000498.3(CYP11B2):c.1066C>T (p.Gln356Ter)	Pathogenic
1455200	NM_000498.3(CYP11B2):c.531del (p.Gln178fs)	Pathogenic
1458193	NM_000498.3(CYP11B2):c.892G>T (p.Glu298Ter)	Pathogenic
1459295	NM_000498.3(CYP11B2):c.217C>T (p.Gln73Ter)	Pathogenic
16878	NM_000498.3(CYP11B2):c.104_109delinsG (p.Val35fs)	Pathogenic
16881	NM_000498.3(CYP11B2):c.554C>T (p.Thr185Ile)	Pathogenic
16884	CYP11B2, IVS2 CONVERSION	Pathogenic
2027037	NM_000498.3(CYP11B2):c.916dup (p.Ala306fs)	Pathogenic
2031382	NM_000498.3(CYP11B2):c.845del (p.Arg282fs)	Pathogenic
2097019	NM_000498.3(CYP11B2):c.1084del (p.Leu362fs)	Pathogenic
2098081	NM_000498.3(CYP11B2):c.895del (p.Leu299fs)	Pathogenic
2109017	NM_000498.3(CYP11B2):c.240-1G>T	Pathogenic
2119763	NM_000498.3(CYP11B2):c.1247T>A (p.Leu416Ter)	Pathogenic
2136711	NM_000498.3(CYP11B2):c.788T>A (p.Ile263Asn)	Pathogenic
2136713	NM_000498.3(CYP11B2):c.508C>T (p.Gln170Ter)	Pathogenic
2423179	NC_000008.10:g.(?143993936)(143994311_?)del	Pathogenic
2674683	NM_000498.3(CYP11B2):c.546dup (p.Ser183fs)	Pathogenic
2674686	NM_000498.3(CYP11B2):c.793C>T (p.Gln265Ter)	Pathogenic
2674688	NM_000498.3(CYP11B2):c.954G>C (p.Thr318=)	Pathogenic
2674696	NM_000498.3(CYP11B2):c.1471C>T (p.Pro491Ser)	Pathogenic
2697591	NM_000498.3(CYP11B2):c.594A>T (p.Glu198Asp)	Pathogenic
2702769	NM_000498.3(CYP11B2):c.499del (p.Asp167fs)	Pathogenic
2703927	NM_000498.3(CYP11B2):c.1140del (p.Leu382fs)	Pathogenic
2704824	NM_000498.3(CYP11B2):c.180_184del (p.Tyr61fs)	Pathogenic

SpliceAI

1591 predictions. Top by Δscore:

Variant	Effect	Δscore
8:142912528:A:AC	donor_gain	1.0000
8:142912529:C:CC	donor_gain	1.0000
8:142914276:C:CA	donor_gain	1.0000
8:142914416:CAC:C	acceptor_gain	1.0000
8:142914419:C:CC	acceptor_gain	1.0000
8:142914419:CT:C	acceptor_loss	1.0000
8:142914424:C:CT	acceptor_gain	1.0000
8:142914424:C:T	acceptor_gain	1.0000
8:142914704:CCGTA:C	donor_gain	1.0000
8:142914708:A:AC	donor_gain	1.0000
8:142914709:C:CC	donor_gain	1.0000
8:142915041:CACA:C	donor_loss	1.0000
8:142915042:ACAC:A	donor_loss	1.0000
8:142915044:ACC:A	donor_loss	1.0000
8:142915045:C:A	donor_loss	1.0000
8:142915045:CCTT:C	donor_gain	1.0000
8:142915081:T:TA	donor_gain	1.0000
8:142915241:CATTC:C	acceptor_gain	1.0000
8:142915242:ATTC:A	acceptor_gain	1.0000
8:142915243:TTC:T	acceptor_gain	1.0000
8:142915243:TTCC:T	acceptor_loss	1.0000
8:142915244:TC:T	acceptor_gain	1.0000
8:142915245:CC:C	acceptor_gain	1.0000
8:142915246:C:CA	acceptor_loss	1.0000
8:142915246:C:CC	acceptor_gain	1.0000
8:142915247:T:G	acceptor_loss	1.0000
8:142917057:A:AC	donor_gain	1.0000
8:142917058:C:CC	donor_gain	1.0000
8:142917058:CAA:C	donor_gain	1.0000
8:142917123:T:TA	donor_gain	1.0000

AlphaMissense

3288 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:142912599:A:C	F443L	0.993
8:142912599:A:T	F443L	0.993
8:142912601:A:G	F443L	0.993
8:142914904:G:C	S200R	0.990
8:142914904:G:T	S200R	0.990
8:142914906:T:G	S200R	0.990
8:142915230:C:A	W137C	0.990
8:142915230:C:G	W137C	0.990
8:142915232:A:G	W137R	0.990
8:142915232:A:T	W137R	0.990
8:142914273:G:C	S315R	0.989
8:142914273:G:T	S315R	0.989
8:142914275:T:G	S315R	0.989
8:142913374:G:C	S344R	0.987
8:142913374:G:T	S344R	0.987
8:142913376:T:G	S344R	0.987
8:142913294:T:A	E371V	0.985
8:142915219:C:G	R141P	0.985
8:142912578:G:C	C450W	0.984
8:142917108:A:G	W116R	0.984
8:142917108:A:T	W116R	0.984
8:142914726:A:G	W260R	0.982
8:142914726:A:T	W260R	0.982
8:142911996:A:G	F499S	0.981
8:142912570:C:G	R453P	0.981
8:142912580:A:G	C450R	0.981
8:142914286:A:G	L311P	0.981
8:142912586:G:T	R448S	0.979
8:142913295:C:T	E371K	0.978
8:142913414:G:T	A331D	0.978

dbSNP variants (sampled 300 via entrez): RS1000182985 (8:142919583 TTTA>T), RS1000921788 (8:142913188 G>A), RS1001157479 (8:142913564 A>C), RS1001183450 (8:142918518 C>T), RS1002584292 (8:142916815 C>T), RS1002643099 (8:142916630 C>G,T), RS1002764645 (8:142911426 G>A,C,T), RS1002935857 (8:142911207 A>G), RS1003528368 (8:142919753 A>G), RS1004313400 (8:142918871 C>T), RS1005277521 (8:142910633 C>A,T), RS1005726427 (8:142912320 C>G,T), RS1005931936 (8:142916389 C>A,G), RS1006012671 (8:142911126 A>G), RS1006065351 (8:142910921 G>A)

Disease associations

OMIM: gene MIM:124080 | disease phenotypes: MIM:203400, MIM:610600, MIM:103900, MIM:606984

GenCC curated gene-disease

Disease	Classification	Inheritance
corticosterone methyloxidase type 2 deficiency	Strong	Autosomal recessive
corticosterone methyloxidase type 1 deficiency	Moderate	Autosomal recessive
familial hypoaldosteronism	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
familial hyperreninemic hypoaldosteronism type 2	Definitive	AR

Mondo (6): corticosterone methyloxidase type 1 deficiency (MONDO:0008751), corticosterone methyloxidase type 2 deficiency (MONDO:0012524), glucocorticoid-remediable aldosteronism (MONDO:0007080), early-onset familial hypoaldosteronism (MONDO:0035320), familial hypoaldosteronism (MONDO:0018541), familial hyperreninemic hypoaldosteronism type 2 (MONDO:0011754)

Orphanet (4): Familial hypoaldosteronism (Orphanet:427), Familial hyperaldosteronism type I (Orphanet:403), Early-onset familial hypoaldosteronism (Orphanet:556030), OBSOLETE: Familial hyperreninemic hypoaldosteronism type 2 (Orphanet:99764)

HPO phenotypes

39 total (30 of 39 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000127	Renal salt wasting
HP:0000360	Tinnitus
HP:0000421	Epistaxis
HP:0000811	Abnormal external genitalia morphology
HP:0000822	Hypertension
HP:0000848	Increased circulating renin concentration
HP:0001278	Orthostatic hypotension
HP:0001290	Generalized hypotonia
HP:0001324	Muscle weakness
HP:0001508	Failure to thrive
HP:0001510	Growth delay
HP:0001944	Dehydration
HP:0001954	Recurrent fever
HP:0001959	Polydipsia
HP:0002013	Vomiting
HP:0002018	Nausea
HP:0002153	Hyperkalemia
HP:0002170	Intracranial hemorrhage
HP:0002315	Headache
HP:0002615	Hypotension
HP:0002900	Hypokalemia
HP:0002902	Hyponatremia
HP:0003623	Neonatal onset
HP:0004319	Decreased circulating aldosterone concentration
HP:0008221	Adrenal hyperplasia
HP:0008872	Feeding difficulties in infancy
HP:0008897	Postnatal growth retardation
HP:0011410	Caesarean section
HP:0011739	Dexamethasone-suppressible primary hyperaldosteronism

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004363_4	Plasma androstenedione levels in resected early stage-receptor positive breast cancer	7.000000e-07
GCST005979_15	Systolic blood pressure	4.000000e-12
GCST006010_12	Mean arterial pressure	9.000000e-11
GCST007094_188	Diastolic blood pressure	6.000000e-10
GCST007095_90	Systolic blood pressure	8.000000e-06
GCST007099_199	Systolic blood pressure	3.000000e-10
GCST007267_336	Systolic blood pressure	1.000000e-10
GCST007703_109	Systolic blood pressure	1.000000e-11
GCST007704_19	Diastolic blood pressure	3.000000e-09
GCST007705_1	Pulse pressure	7.000000e-06
GCST007706_31	Mean arterial pressure	1.000000e-11
GCST007706_54	Mean arterial pressure	1.000000e-11
GCST007707_31	Hypertension	2.000000e-08
GCST007707_60	Hypertension	3.000000e-08
GCST007928_81	Medication use (diuretics)	3.000000e-09
GCST011141_21	Hypertension	3.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007972	androstenedione measurement
EFO:0006335	systolic blood pressure
EFO:0006340	mean arterial pressure
EFO:0006336	diastolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0009928	Diuretic use measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
C563177	Glucocorticoid-Remediable Aldosteronism (supp.)
C564638	Hyperreninemic Hypoaldosteronism, Familial, 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2722 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

12 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 281,966 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL106	FLUCONAZOLE	4	58,942
CHEMBL1397	POSACONAZOLE	4	541
CHEMBL1444	LETROZOLE	4	81,122
CHEMBL157101	KETOCONAZOLE	4	75,361
CHEMBL254328	ABIRATERONE	4	22,316
CHEMBL3099695	OSILODROSTAT	4	347
CHEMBL681	ETOMIDATE	4	8,462
CHEMBL934	METYRAPONE	4	2,893
CHEMBL4113975	BAXDROSTAT	3	16
CHEMBL5095105	LORUNDROSTAT	3	35
CHEMBL287677	DEXFADROSTAT	2	169
CHEMBL9298	FADROZOLE	2	31,762

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1799998	Efficacy	3	benazepril;imidapril	Essential hypertension
rs1799998	Efficacy	3	candesartan	Hypertension

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1799998	CYP11B2	3	2.50	2	benazepril;imidapril;candesartan

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP11, CYP17, CYP19, CYP20 and CYP21 families

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
osilodrostat	Inhibition	9.7	pIC50
fadrozole	Inhibition	9.1	pKi
lorundrostat	Inhibition	8.9	pKi
dexfadrostat	Inhibition	7.97	pIC50
baxdrostat	Inhibition	7.89	pKi
vicadrostat	Inhibition	7.8	pIC50
metyrapone	Inhibition	7.1	pIC50

Binding affinities (BindingDB)

1017 measured of 1102 human assays (1102 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(E)-2-(4-Chlorophenoxy)-3- (dimethylamino)-1-(2-methoxyphenyl)prop- 2-en-1-one	EC50	0.001 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[(Z)-1-(2-Benzyloxybenzoyl)-2- (dimethylamino)vinyloxy]benzonitrile	EC50	0.001 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00174	EC50	0.003 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00182	EC50	0.005 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[2-(Pyridin-4-ylmethoxy)phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.007 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00175	EC50	0.007 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00172	EC50	0.011 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00173	EC50	0.011 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-(2-Fluoro-3-hydroxyphenyl)-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.017 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-1-[(2-Chlorobenzoyl)-2- (dimethylamino)vinyloxy]benzonitrile	EC50	0.018 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00183	EC50	0.028 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
Methyl 3-[(E)-2-(4-cyanophenoxy)- 3-(dimethylamino)prop-2-enoyl]benzoate	EC50	0.031 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00129	EC50	0.032 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[3-[[3-Fluoro-3-(hydroxymethyl)azetidin-1-yl]methyl]phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.036 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00162	EC50	0.038 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00131	EC50	0.046 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[3-[(6-Fluoropyridin-2-yl)oxymethyl]phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.048 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(rac)-6-[4-[1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.049 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
4-[3-[3-(pyridin-3-ylmethoxy)phenyl]pyrazolidin-4-yl]oxybenzonitrile	EC50	0.051 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-2-(4-Chlorophenoxy)-1-(2- chlorophenyl)-3-(dimethylamino)prop-2-en- 1-one	EC50	0.052 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[3-(Pyridin-2-ylmethoxy)phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.052 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[(Z)-1-(3-Benzyloxybenzoyl)-2- (dimethylamino)vinyloxy]benzonitrile	EC50	0.053 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(rac)-6-[4-[1-(1-Acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-7-fluoro-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.067 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
4-[(Z)-1-(2-Chloro-3-fluoro- benzoyl)- (dimethylamino)vinyloxy]benzonitrile	EC50	0.069 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(+)-6-[4-[(1R)-1-(1-acetylpiperidin-4-yl)ethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.074 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
(E)-2-(4-Chlorophenoxy)-1-[2- (difluoromethoxy)phenyl]-3- (dimethylamino)prop-2-en-1-one	EC50	0.076 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00074	EC50	0.076 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
4-[[3-(3-Hydroxyphenyl)-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.083 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[3-(Hydroxymethyl)phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.085 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00133	EC50	0.094 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
1-methyl-6-[5-[(6-methyl-2-pyridinyl)sulfanylmethyl]-3-pyridinyl]-3,4-dihydroquinolin-2-one	EC50	0.1 nM	US-9458135: Dihydroquinoline-2-one derivatives
4-[[5-(3-Butoxyphenyl)-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.102 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00072	EC50	0.133 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
4-[(E)-1-(2-Chlorobenzoyl)-2- (dimethylamino)vinyloxy]-3-fluoro- benzonitrile	EC50	0.134 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
4-[[3-[3-(Morpholin-4-ylmethyl)phenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.139 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(rac)-4-[[3-[1-(1-Methylpyrazole-4-carbonyl)piperidin-3-yl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.15 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-2-(4-Chlorophenoxy)-1-(2,4- difluorophenyl)-3-(dimethylamino)prop-2- en-1-one	EC50	0.159 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00117	EC50	0.159 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-1-[(2,3-Difluorobenzoyl)-2-(dimethylamino)vinyloxy]benzonitrile	EC50	0.161 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-2-(4-Chlorophenoxy)-3- (dimethylamino)-1-(2-fluorophenyl)prop-2- en-1-one	EC50	0.167 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00176	EC50	0.171 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
6-[4-[(1-Acetyl-4-piperidyl)methyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.184 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
4-[(E)-1-(3-Chloro-2-fluoro- benzoyl)-2- (dimethylamino)vinyloxy]benzonitrile	EC50	0.191 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
CHEM-US-00130	EC50	0.198 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(rac)-4-[[3-[3-(1-Acetylpyrrolidin-3-yl)oxyphenyl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.215 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
5-Chloro-6-[4-[(2-ethylsulfonyl-2-azaspiro[3.3]heptan-6-yl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.215 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
6-[4-[(1-Ethylsulfonyl-4-piperidyl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.216 nM	US-9796702: Dihydroquinoline pyrazolyl compounds
(rac)-3-Fluoro-4-[[5-[1-(1-methylpyrazole-4-carbonyl)piperidin-3-yl]-1H-pyrazol-4-yl]oxy]benzonitrile	EC50	0.231 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
(E)-1-(2-Chloro-3-fluoro-phenyl)-2- (4-chlorophenoxy)-3-(dimethylamino)prop-2- en-1-one	EC50	0.262 nM	US-9790217: Pyridinyloxy- and phenyloxy-pyrazolyl compounds
6-[4-[(1-Acetyl-4-piperidyl)methyl]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one	EC50	0.266 nM	US-9796702: Dihydroquinoline pyrazolyl compounds

ChEMBL bioactivities

3025 potent at pChembl≥5 of 3043 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	EC50	0.01	nM	CHEMBL5794024
11.00	EC50	0.01	nM	CHEMBL5955547
11.00	EC50	0.01	nM	CHEMBL6056586
11.00	EC50	0.01	nM	CHEMBL5993024
11.00	EC50	0.01	nM	CHEMBL5806425
10.96	EC50	0.011	nM	CHEMBL5846526
10.96	EC50	0.011	nM	CHEMBL5754409
10.92	EC50	0.012	nM	CHEMBL3916961
10.92	EC50	0.012	nM	CHEMBL5849911
10.92	EC50	0.012	nM	CHEMBL5767596
10.92	EC50	0.012	nM	CHEMBL5877749
10.89	EC50	0.013	nM	CHEMBL5789906
10.85	EC50	0.014	nM	CHEMBL4632981
10.85	EC50	0.014	nM	CHEMBL5960934
10.82	EC50	0.015	nM	CHEMBL5935291
10.82	EC50	0.015	nM	CHEMBL5901252
10.82	EC50	0.015	nM	CHEMBL5965994
10.82	EC50	0.015	nM	CHEMBL5870745
10.80	EC50	0.016	nM	CHEMBL5760532
10.77	EC50	0.017	nM	CHEMBL5928932
10.77	EC50	0.017	nM	CHEMBL5949511
10.77	EC50	0.017	nM	CHEMBL5848123
10.74	EC50	0.018	nM	CHEMBL5965425
10.74	EC50	0.018	nM	CHEMBL6020579
10.72	EC50	0.019	nM	CHEMBL5947135
10.72	EC50	0.019	nM	CHEMBL5971655
10.72	EC50	0.019	nM	CHEMBL5840628
10.70	EC50	0.02	nM	CHEMBL5930370
10.70	EC50	0.02	nM	CHEMBL5876457
10.70	EC50	0.02	nM	CHEMBL5816213
10.68	EC50	0.021	nM	CHEMBL5817118
10.62	EC50	0.024	nM	CHEMBL5755111
10.62	EC50	0.024	nM	CHEMBL5858242
10.62	EC50	0.024	nM	CHEMBL5979599
10.60	EC50	0.025	nM	CHEMBL5811264
10.60	EC50	0.025	nM	CHEMBL5778806
10.59	EC50	0.026	nM	CHEMBL5878312
10.57	EC50	0.027	nM	CHEMBL5993382
10.57	EC50	0.027	nM	CHEMBL5850242
10.55	EC50	0.028	nM	CHEMBL5844639
10.55	EC50	0.028	nM	CHEMBL5840143
10.55	EC50	0.028	nM	CHEMBL6039670
10.55	EC50	0.028	nM	CHEMBL5919201
10.54	EC50	0.029	nM	CHEMBL5843772
10.52	EC50	0.03	nM	CHEMBL5882012
10.52	EC50	0.03	nM	CHEMBL6062016
10.49	EC50	0.032	nM	CHEMBL5844431
10.48	EC50	0.033	nM	CHEMBL5918071
10.47	EC50	0.034	nM	CHEMBL5935643
10.42	EC50	0.038	nM	CHEMBL5899256

PubChem BioAssay actives

1440 with measured affinity, of 1939 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-isoquinolin-4-yl-1-methyl-3,4-dihydroquinolin-2-one	389805: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0001	uM
Etomidate	553066: Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate	ic50	0.0001	uM
4-(6,7-difluoro-1-methylbenzimidazol-2-yl)isoquinoline	1177651: Inhibition of human aldosterone synthase expressed in V79 MZ cells	ic50	0.0001	uM
5-chloro-2-[5-[2-(1-ethylpyrazole-4-carbonyl)-2,6-diazaspiro[3.3]heptan-6-yl]-3-pyridinyl]-3,3-dimethylisoindol-1-one	2109202: Inhibition of human CYP11B2 stably expressed in G-402 cells	ic50	0.0002	uM
3-(methoxymethyl)-5-(6-methoxynaphthalen-2-yl)pyridine	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0002	uM
3-(1-methoxyethyl)-5-(6-methoxynaphthalen-2-yl)pyridine	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0002	uM
6-isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one	389805: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0002	uM
6-(5-methoxy-3-pyridinyl)-1-methyl-3,4-dihydroquinolin-2-one	389805: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0002	uM
Osilodrostat	1154696: Inhibition of CYP11B2 (unknown origin)	ic50	0.0002	uM
6-isoquinolin-4-yl-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-11-one	592041: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells assessed as conversion of [4-14C]-11-deoxycorticosterone substrate by HPTLC assay	ic50	0.0002	uM
7-isoquinolin-4-yl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one	592041: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells assessed as conversion of [4-14C]-11-deoxycorticosterone substrate by HPTLC assay	ic50	0.0002	uM
1-cyclopropyl-2-(4,5-dimethyl-3-pyridinyl)-5,6-difluorobenzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0002	uM
2-[5-(4-chloro-7-fluoroindazol-1-yl)-3-pyridinyl]propan-2-ol	1474789: Inhibition of human CYP11B2-CLE9 expressed in Chinese hamster V79 cells using 11-deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition measured for 3 hrs by HTRF assay	ic50	0.0002	uM
2-fluoro-4-[5-(2-methyl-1,3-dioxolan-2-yl)-3-pyridinyl]benzonitrile	1977386: Inhibition of human CYP11B2 stably transfected in mouse Y-1 cells using deoxycortisol or deoxycorticosterone as substrate incubated for 48 hrs by radioimmuno assay	ic50	0.0003	uM
2-[5-(4,7-difluoroindazol-1-yl)-3-pyridinyl]propan-2-ol	1474789: Inhibition of human CYP11B2-CLE9 expressed in Chinese hamster V79 cells using 11-deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition measured for 3 hrs by HTRF assay	ic50	0.0003	uM
6-isoquinolin-4-yl-1,4-dihydro-3,1-benzoxazin-2-one	1191378: Inhibition of CYP11B2 in human V79MZ cells using [3H]-11-deoxycorticosterone as substrate incubated for 1 hr prior to substrate addition measured after 45 mins by HPLC analysis	ic50	0.0003	uM
(1S)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxo-1,4-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol	493924: Inhibition of human recombinant CYP11B2 by cell-based assay	ic50	0.0003	uM
2-[5-(1-cyclopropyl-5,6-difluorobenzimidazol-2-yl)-3-pyridinyl]propan-2-ol	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0003	uM
[4-(4-fluorophenyl)sulfanylpyrimidin-5-yl]-(1-methylsulfonylpiperidin-4-yl)methanol	1444794: Inhibition of human CYP11B2 expressed in HEK293A cells using deoxycorticosterone as substrate pretreated for 1 hr followed by substrate addition measured after 1 hr by HTRF assay	ic50	0.0004	uM
6-chloro-1-cyclopropyl-5-fluoro-2-pyridin-3-ylbenzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0004	uM
1-cyclopropyl-5,6-difluoro-2-(5-methoxy-3-pyridinyl)benzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0004	uM
3-(4-fluorophenyl)-4-[(5R)-6,7,8,9-tetrahydro-5H-imidazo[1,5-a]azepin-5-yl]benzonitrile	1059816: Inhibition of human recombinant CYP11B2 using 11-deoxycorticosterone as substrate by cell-based assay	ic50	0.0004	uM
5-chloro-3,3-dimethyl-2-[5-[1-(1-methylpyrazole-4-carbonyl)azetidin-3-yl]oxy-3-pyridinyl]isoindol-1-one	1658216: Inhibition of human CYP11B2 expressed in human renal leiomyoblastoma cells harboring FDXR/FDX using 1-deoxycorticosterone as substrate by HTRF assay	ic50	0.0005	uM
1-[5-(6-methoxynaphthalen-2-yl)-3-pyridinyl]ethanol	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0005	uM
4-(6-methoxy-3-methyl-3,4-dihydronaphthalen-2-yl)isoquinoline	2109203: Inhibition of human CYP11B2 expressed in human NCI-H295 cells incubated for 48 hrs by radioimmuno assay	ic50	0.0005	uM
7-isoquinolin-4-yl-4H-1,4-benzoxazin-3-one	1191378: Inhibition of CYP11B2 in human V79MZ cells using [3H]-11-deoxycorticosterone as substrate incubated for 1 hr prior to substrate addition measured after 45 mins by HPLC analysis	ic50	0.0005	uM
1-cyclopropyl-5,6-difluoro-2-(5-fluoro-4-methyl-3-pyridinyl)benzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0005	uM
2-phenyl-5-[(5-phenyl-3-pyridinyl)methyl]pyridine	765521: Inhibition of human CYP11B2 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate	ic50	0.0005	uM
3-cyclopropyl-6-fluoro-2-pyridin-3-ylbenzimidazole-5-carbonitrile	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0006	uM
N-(4-fluorophenyl)-5-(1-methylsulfonylpiperidin-4-yl)sulfanylpyrimidin-4-amine	2109497: Inhibition of human CYP11B2 expressed in HEK293-A cells harboring FDXR/FDX using deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr	ic50	0.0006	uM
4-(6-methoxynaphthalen-2-yl)isoquinoline	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0006	uM
6-(4-methyl-3-pyridinyl)naphthalene-2-carbonitrile	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0006	uM
6-(5-methoxy-3-pyridinyl)-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-11-one	592041: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells assessed as conversion of [4-14C]-11-deoxycorticosterone substrate by HPTLC assay	ic50	0.0006	uM
1-cyclopropyl-5,6-difluoro-2-(4-methoxy-5-methyl-3-pyridinyl)benzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0006	uM
4-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)isoquinoline	1332279: Inhibition of human CYP11B2-CLE9 expressed in Chinese hamster V79 cells using 11-deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition measured after 3 hrs by HTRF assay	ic50	0.0006	uM
1-(5-isoquinolin-4-ylindol-1-yl)ethanone	1154700: Inhibition of human CYP11B2 expressed in hamster V79MZh cells using deoxycorticosterone as substrate	ic50	0.0006	uM
2,2,2-trifluoro-1-[4-(4-fluoroanilino)pyrimidin-5-yl]-1-(1-methylsulfonylpiperidin-4-yl)ethanol	1444794: Inhibition of human CYP11B2 expressed in HEK293A cells using deoxycorticosterone as substrate pretreated for 1 hr followed by substrate addition measured after 1 hr by HTRF assay	ic50	0.0007	uM
6-[5-(2-fluorophenyl)-3-pyridinyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-11-one	592041: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells assessed as conversion of [4-14C]-11-deoxycorticosterone substrate by HPTLC assay	ic50	0.0007	uM
1-(5-isoquinolin-4-yl-2,3-dihydroindol-1-yl)ethanone	1154700: Inhibition of human CYP11B2 expressed in hamster V79MZh cells using deoxycorticosterone as substrate	ic50	0.0007	uM
4-[6-(diethylamino)pyrazin-2-yl]-2-fluorobenzonitrile	1977386: Inhibition of human CYP11B2 stably transfected in mouse Y-1 cells using deoxycortisol or deoxycorticosterone as substrate incubated for 48 hrs by radioimmuno assay	ic50	0.0008	uM
N-(4-fluorophenyl)-5-(1-methylsulfonylpiperidin-4-yl)sulfonylpyrimidin-4-amine	2109497: Inhibition of human CYP11B2 expressed in HEK293-A cells harboring FDXR/FDX using deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr	ic50	0.0008	uM
methyl 5-(6-methoxynaphthalen-2-yl)pyridine-3-carboxylate	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0008	uM
3-(6-methoxynaphthalen-2-yl)-4-methylpyridine	362124: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	ic50	0.0008	uM
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(propan-2-yloxymethyl)-1,4-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide	493924: Inhibition of human recombinant CYP11B2 by cell-based assay	ic50	0.0008	uM
6-chloro-1-cyclopropyl-5-fluoro-2-(5-fluoro-3-pyridinyl)benzimidazole	1229390: Inhibition of human CYP11B2 expressed in V79 cells incubated for 1 hr before 11-deoxycorticosterone substrate addition by HTRF-based assay	ic50	0.0008	uM
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile	1154700: Inhibition of human CYP11B2 expressed in hamster V79MZh cells using deoxycorticosterone as substrate	ic50	0.0008	uM
4-[6-(dimethylamino)pyrazin-2-yl]-2-fluorobenzonitrile	1977386: Inhibition of human CYP11B2 stably transfected in mouse Y-1 cells using deoxycortisol or deoxycorticosterone as substrate incubated for 48 hrs by radioimmuno assay	ic50	0.0009	uM
2-fluoro-4-[5-(4-methyl-1,3-dioxolan-2-yl)-3-pyridinyl]benzonitrile	1977386: Inhibition of human CYP11B2 stably transfected in mouse Y-1 cells using deoxycortisol or deoxycorticosterone as substrate incubated for 48 hrs by radioimmuno assay	ic50	0.0009	uM
N-(4-fluorophenyl)-5-(4-methylsulfonylpiperazin-1-yl)sulfonylpyrimidin-4-amine	2109497: Inhibition of human CYP11B2 expressed in HEK293-A cells harboring FDXR/FDX using deoxycorticosterone as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr	ic50	0.0009	uM
7-(5-methoxy-3-pyridinyl)-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one	592041: Inhibition of human CYP11B2 expressed in hamster V79 MZh cells assessed as conversion of [4-14C]-11-deoxycorticosterone substrate by HPTLC assay	ic50	0.0009	uM

CTD chemical–gene interactions

109 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Colforsin	decreases expression, increases expression, decreases reaction, increases reaction, affects cotreatment (+1 more)	10
3,4,5,3’,4’-pentachlorobiphenyl	increases activity, increases expression, increases reaction, affects cotreatment	6
Aldosterone	increases chemical synthesis, increases hydroxylation, affects chemical synthesis	5
torcetrapib	increases expression, decreases reaction	4
Fadrozole	decreases activity	4
Flame Retardants	increases expression, decreases expression	3
Ketoconazole	affects binding, decreases activity, increases expression, increases reaction	3
tributyltin	affects cotreatment, increases expression	2
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression, affects cotreatment	2
perfluorooctane sulfonic acid	increases expression, affects cotreatment	2
2,2’,4,4’-tetrabromodiphenyl ether	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases expression	2
Corticosterone	affects metabolic processing, increases chemical synthesis, increases hydroxylation	2
Cortodoxone	affects metabolic processing, increases metabolic processing	2
Desoxycorticosterone	increases chemical synthesis, affects metabolic processing, increases hydroxylation	2
Potassium	increases expression, decreases reaction	2
Valproic Acid	increases expression, increases methylation	2
8-Bromo Cyclic Adenosine Monophosphate	increases expression	2
Halogenated Diphenyl Ethers	decreases expression, increases expression	2
fluorene-9-bisphenol	affects reaction, increases expression, decreases expression	1
triptolide	decreases expression, affects cotreatment	1
perflubron	increases expression	1
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	increases expression, affects cotreatment	1
alternariol	increases expression	1
naringin	decreases reaction, increases expression	1
bisphenol A	decreases expression	1
deoxynivalenol	increases expression	1
4,4’-bisphenol F	decreases expression	1
2,4,5,2’,5’-pentachlorobiphenyl	increases expression	1

ChEMBL screening assays

147 unique, capped per target: 135 binding, 12 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1002226	Binding	Inhibition of human CYP11B2 expressed in hamster V79 MZh cells	Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. — J Med Chem
CHEMBL2433420	ADMET	Inhibition of human CYP11B2	Emerging technologies for metabolite generation and structural diversification. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_4710	V79MZh11B2	Spontaneously immortalized cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.